Gastrointestinal stromal tumors--a review

Area of Science:

• Gastroenterology
• Oncology
• Molecular Biology

Background:

• Gastrointestinal stromal tumors (GISTs) are intra-abdominal mesenchymal tumors.
• GISTs are characterized by KIT protein expression or activating mutations in KIT or PDGFRA genes.
• Tumor malignancy potential is assessed by size and proliferation, with variable clinical behavior.

Purpose of the Study:

• To define Gastrointestinal stromal tumors (GISTs).
• To describe the molecular basis of GISTs, focusing on KIT and PDGFRA.
• To outline current and emerging therapeutic strategies for GISTs.

Main Methods:

• Review of GISTs definition and diagnostic criteria.
• Analysis of molecular mechanisms involving KIT and PDGFRA mutations.
• Summary of current treatment modalities, including imatinib mesylate.

Main Results:

• GISTs express KIT protein; mutations in KIT or PDGFRA genes are common.
• Imatinib mesylate is the standard therapy for advanced GIST, inhibiting KIT and PDGFRA.
• Conventional chemotherapy is largely ineffective for GISTs.

Conclusions:

• GISTs are defined by specific molecular markers (KIT/PDGFRA).
• Imatinib mesylate represents a significant advancement in GIST treatment.
• Ongoing research focuses on adjuvant imatinib and novel targeted therapies for GISTs.